Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance

详细信息    查看全文

• 作者：Sally Temraz ; ^{st29@aub.edu.lb" class="auth_mail" title="E-mail the corresponding author}Author Vitae ; Deborah Mukherji ; Ali Shamseddine
• 关键词：Colorectal cancer ; EGFR ; Monoclonal antibodies ; Drug resistance ; HER3
• 刊名：Critical Reviews in Oncology and Hematology
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：101
• 期：Complete
• 页码：151-157
• 全文大小：849 K

文摘

Multiple genetic alterations have been associated with resistance to anti–EGFR therapy in metastatic colorectal cancer (CRC) patients. Research has been mainly focused on driver mutations in KRAS, NRAS, BRAF and PI3K. However, recent evidence suggests a crucial role for non-genetic mechanisms in conferring resistance to anti-EGFR therapy. Specifically, the HER3 receptor is capable of heterodimerizing with multiple EGFR family members resulting in downstream activation of the PI3K and MAPK pathways. Monoclonal antibodies targeted against the HER3 receptor are being investigated in clinical trials; however, preliminary data has shown limited clinical activity. Thus, given the relevance of the HER3 receptor in activating downstream effector pathways and in conferring resistance to anti-EGFR therapy, the therapeutic targeting of HER3 in combination with primary drivers of the tumor is also being investigated. Here, we review the role of HER3 as a promoter of clinical resistance to EGFR therapy and discuss therapeutic approaches that could potentially overcome this resistance.